These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9666789)

  • 21. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
    Linet OI; Ogrinc FG
    N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incidence and management of priapism in Western Australia: a 16 year audit.
    Earle CM; Stuckey BG; Ching HL; Wisniewski ZS
    Int J Impot Res; 2003 Aug; 15(4):272-6. PubMed ID: 12934055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myocardial infarction associated with intra-cavernosal administration of alprostadil in a patient with spinal cord injury and paraplegia.
    Vaidyanathan S; Krishnan KR
    Spinal Cord; 1996 Dec; 34(12):754-5. PubMed ID: 8961437
    [No Abstract]   [Full Text] [Related]  

  • 24. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.
    Costabile RA; Spevak M; Fishman IJ; Govier FE; Hellstrom WJ; Shabsigh R; Nemo KJ; Rapport JL; Tam PY; Weldon KL; Gesundheit N
    J Urol; 1998 Oct; 160(4):1325-8. PubMed ID: 9751346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Special precautions to be observed while using alprostadil in patients with spinal cord injury.
    Vaidyanathan S; Soni BM; Krishnan KR
    Spinal Cord; 1997 Jun; 35(6):402-3. PubMed ID: 9194266
    [No Abstract]   [Full Text] [Related]  

  • 27. An overview and expert opinion on the use of alprostadil in the treatment of sexual dysfunction.
    Costabile RA; Mammen T; Hwang K
    Expert Opin Pharmacother; 2008 Jun; 9(8):1421-9. PubMed ID: 18473716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
    Seyam R; Mohamed K; Akhras AA; Rashwan H
    Int J Impot Res; 2005; 17(4):346-53. PubMed ID: 15772683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical conversations: intraurethral alprostadil (MUSE). Interview by Patricia Bates.
    Lewis J; Helfrick B; Marzucco J
    Urol Nurs; 1997 Dec; 17(4):159-61. PubMed ID: 9451246
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prostaglandin in the treatment of impotence].
    Tammela T
    Duodecim; 1998; 114(4):371-5. PubMed ID: 11466950
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs.
    Kulmala RV; Tamella TL
    Int J Impot Res; 1995 Jun; 7(2):131-6. PubMed ID: 7496442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED.
    Padma-Nathan H; Steidle C; Salem S; Tayse N; Yeager J; Harning R
    Int J Impot Res; 2003 Feb; 15(1):10-7. PubMed ID: 12605235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.
    Padma-Nathan H; Hellstrom WJ; Kaiser FE; Labasky RF; Lue TF; Nolten WE; Norwood PC; Peterson CA; Shabsigh R; Tam PY; Place VA; Gesundheit N
    N Engl J Med; 1997 Jan; 336(1):1-7. PubMed ID: 8970933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections.
    Lowe FC; Jarow JP
    Urology; 1993 Jul; 42(1):51-3; discussion 53-4. PubMed ID: 8392235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of colour duplex ultrasonography after transurethral alprostadil and intracavernous alprostadil in the assessment of erectile dysfunction.
    Ahn HS; Lee SW; Yoon SJ; Hann HJ; Hong JM
    J Int Med Res; 2004; 32(3):317-23. PubMed ID: 15174226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prostaglandin E1 injection in erectile dysfunction. Current diagnostic and therapeutic possibilities].
    Schrey A
    Fortschr Med; 1990 Oct; 108(30):577-80. PubMed ID: 2245960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
    Shabsigh R; Padma-Nathan H; Gittleman M; McMurray J; Kaufman J; Goldstein I
    Urology; 2000 Apr; 55(4):477-80. PubMed ID: 10736486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The actual incidence of papaverine-induced priapism in patients with erectile dysfunction following penile colour Doppler ultrasonography.
    Kilic M; Serefoglu EC; Ozdemir AT; Balbay MD
    Andrologia; 2010 Feb; 42(1):1-4. PubMed ID: 20078509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New developments in self-injection therapy for erectile dysfunction.
    Gingell JC
    Br J Urol; 1998 Apr; 81(4):599-603. PubMed ID: 9598634
    [No Abstract]   [Full Text] [Related]  

  • 40. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.